Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of SHR2285 in Healthy Subjects
NCT04229433Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in thrombosis comparing SHR2285 with Placebo (2 arms). Primary endpoint: Number of subjects with adverse events and serious adverse events. Started Aug 2020; status: completed.
02
Drugs
shr2285
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT04229433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04229433.